Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

An economic model of long-term use of celecoxib in patients with osteoarthritis.

Loyd M, Rublee D, Jacobs P.

BMC Gastroenterol. 2007 Jul 4;7:25.

2.

A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.

Brereton N, Pennington B, Ekelund M, Akehurst R.

J Med Econ. 2014 Sep;17(9):677-84. doi: 10.3111/13696998.2014.933111. Epub 2014 Jun 30.

PMID:
24914585
3.

Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.

Jansen JP, Gaugris S, Choy EH, Ostor A, Nash JT, Stam W.

Pharmacoeconomics. 2010;28(4):323-44. doi: 10.2165/11314690-000000000-00000.

PMID:
20222755
4.

Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.

Bessette L, Risebrough N, Mittmann N, Roussy JP, Ho J, Zlateva G.

J Med Econ. 2009 Sep;12(3):246-58. doi: 10.3111/13696990903288970.

PMID:
19743942
6.
7.

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.

Spiegel BM, Targownik L, Dulai GS, Gralnek IM.

Ann Intern Med. 2003 May 20;138(10):795-806. Review.

PMID:
12755551
8.

Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.

Al MJ, Maniadakis N, Grijseels EW, Janssen M.

Value Health. 2008 Jul-Aug;11(4):589-99. doi: 10.1111/j.1524-4733.2007.00303.x. Epub 2008 Jan 8.

9.

The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.

Brereton N, Winn B, Akehurst R.

J Med Econ. 2012;15(3):465-72. doi: 10.3111/13696998.2012.659778. Epub 2012 Feb 14.

PMID:
22260652
10.

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.

Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G; SUCCESS-I Investigators.

Am J Med. 2006 Mar;119(3):255-66. Erratum in: Am J Med. 2006 Sep;119(9):801.

PMID:
16490472
11.

Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.

Capel M, Tornero J, Zamorano JL, Oyagüez I, Casado MÁ, Sánchez-Covisa J, Lanas A.

Reumatol Clin. 2014 Jul-Aug;10(4):210-7. doi: 10.1016/j.reuma.2013.11.009. Epub 2013 Dec 29. English, Spanish.

12.

Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration.

Schaefer M, DeLattre M, Gao X, Stephens J, Botteman M, Morreale A.

Curr Med Res Opin. 2005 Jan;21(1):47-60.

PMID:
15881475
13.

Cost-effectiveness of treatment strategies for osteoarthritis of the knee in Taiwan.

Yen ZS, Lai MS, Wang CT, Chen LS, Chen SC, Chen WJ, Hou SM.

J Rheumatol. 2004 Sep;31(9):1797-803.

PMID:
15338503
14.

[Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].

De Lossada A, Oteo-Álvaro Á, Giménez S, Oyagüez I, Rejas J.

Semergen. 2016 May-Jun;42(4):235-43. doi: 10.1016/j.semerg.2015.04.008. Epub 2015 May 23. Spanish.

PMID:
26006311
15.

Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.

Katz JN, Smith SR, Collins JE, Solomon DH, Jordan JM, Hunter DJ, Suter LG, Yelin E, Paltiel AD, Losina E.

Osteoarthritis Cartilage. 2016 Mar;24(3):409-18. doi: 10.1016/j.joca.2015.10.006. Epub 2015 Oct 23.

16.

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M.

Appl Health Econ Health Policy. 2013 Jun;11(3):219-36. doi: 10.1007/s40258-013-0031-3.

PMID:
23616247
17.

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group.

BMJ. 2009 Jul 14;339:b2538. doi: 10.1136/bmj.b2538.

18.

Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.

You JH, Lee KK, Chan TY, Lau WH, Chan FK.

Aliment Pharmacol Ther. 2002 Dec;16(12):2089-96.

19.

Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.

Wielage R, Bansal M, Wilson K, Klein R, Happich M.

Spine (Phila Pa 1976). 2013 May 15;38(11):936-46. doi: 10.1097/BRS.0b013e31828264f9.

PMID:
23250234
20.

Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.

Chancellor JV, Hunsche E, de Cruz E, Sarasin FP.

Pharmacoeconomics. 2001;19 Suppl 1:59-75.

PMID:
11280106

Supplemental Content

Support Center